Kamada (KMDA) Cost of Revenue (2012 - 2026)
Kamada's (KMDA) quarterly Cost of Revenue came in at $26.1 million in Q1 2026, up 12.27% YoY from $23.3 million in Q1 2025, and down 5.73% on a QoQ basis from $27.7 million in Q4 2025.
Kamada (KMDA) Cost of Revenue (2012 - 2026) Analysis & Trends
Kamada (KMDA) has 15 years of Cost of Revenue data on file, last reported at $26.1 million in Q1 2026.
- Quarterly Cost of Revenue rose 12.27% year-over-year to $26.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $25.9 billion (up 9.81% YoY) and the FY2025 annual result came in at $104.1 million, up 14.36% from the prior year.
- Cost of Revenue slipped to $26.1 million in Q1 2026, from $27.7 million in the prior quarter.
- In the past five years, Cost of Revenue ranged from a high of $25.8 billion in Q2 2025 to a low of $16.3 million in Q2 2022.
- A 5-year average of $5.2 billion and a median of $24.5 million in 2024 frame the typical range for Cost of Revenue.
- Annual changes were most pronounced in 2023 — Cost of Revenue jumped 112287.59% — and 2024, when it slumped 99.89%.
- Tracing KMDA's Cost of Revenue over 5 years: stood at $30.1 million in 2022, then slipped by 26.96% to $22.0 million in 2023, then fell by 0.21% to $22.0 million in 2024, then rose by 26.11% to $27.7 million in 2025, then slipped by 5.73% to $26.1 million in 2026.
- The last three Cost of Revenue figures came in at $26.1 million (Q1 2026), $27.7 million (Q4 2025), and $27.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.81 Bn | 42.84 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.29 Bn | 39.63 Bn | 2.15 Bn | 1.99 Bn |
| 3 | Zoetis | 31.59 Bn | 29.91 Bn | 1.05 Bn | 673.00 Mn |
| 4 | Takeda Pharmaceutical | 28.67 Bn | 22.88 Bn | 5.10 Bn | 2.55 Bn |
| 5 | United Therapeutics | 22.24 Bn | 19.58 Bn | 683.80 Mn | 99.50 Mn |
| 6 | Viatris | 18.79 Bn | 17.91 Bn | 1.46 Bn | 2.30 Bn |
| 7 | Neurocrine Biosciences | 15.71 Bn | 15.32 Bn | 935.80 Mn | 23.20 Mn |
| 8 | Elanco Animal Health | 12.09 Bn | 11.56 Bn | 798.00 Mn | 570.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Kamada | 456.56 Mn | 427.09 Mn | 22.47 Mn | 32.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 32.45 Mn |
| Jun 30, 2026 | 32.45 Mn |
| Mar 31, 2026 | 26.12 Mn |
| Mar 31, 2026 | 26.12 Mn |
| Dec 31, 2025 | 27.71 Mn |
| Dec 31, 2025 | 27.71 Mn |
| Sep 30, 2025 | 27.25 Mn |
| Sep 30, 2025 | 27.25 Mn |
| Jun 30, 2025 | 25.83 Bn |
| Jun 30, 2025 | 25.83 Bn |
| Mar 31, 2025 | 23.27 Mn |
| Mar 31, 2025 | 23.27 Mn |
| Dec 31, 2024 | 21.97 Mn |
| Dec 31, 2024 | 21.97 Mn |
| Sep 30, 2024 | 24.51 Mn |
| Sep 30, 2024 | 24.51 Mn |
| Jun 30, 2024 | 23.52 Bn |
| Jun 30, 2024 | 23.52 Bn |
| Mar 31, 2024 | 20.99 Mn |
| Mar 31, 2024 | 20.99 Mn |